Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$9.01
+4.1%
$9.09
$0.06
$14.93
$6.69M0.98556,426 shs8,587 shs
Clene Inc. stock logo
CLNN
Clene
$3.93
+2.7%
$3.61
$2.28
$6.96
$32.46M0.5588,864 shs765 shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.53
+1.0%
$2.79
$2.11
$9.19
$22.30M1.14386,422 shs19,276 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$6.46
+2.5%
$6.92
$5.35
$28.34
$23.77M-1.95167,441 shs4,535 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%+0.83%+0.43%+1.20%-75.02%
Clene Inc. stock logo
CLNN
Clene
0.00%+6.41%-10.75%+26.49%-11.78%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%0.00%-10.64%-15.15%-28.81%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%-9.35%-7.08%-11.39%-74.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.3627 of 5 stars
3.50.00.00.02.00.00.0
Clene Inc. stock logo
CLNN
Clene
2.9734 of 5 stars
3.65.00.00.00.02.50.6
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
1.86 of 5 stars
3.33.00.00.03.10.00.0
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.6193 of 5 stars
3.34.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$275.002,953.86% Upside
Clene Inc. stock logo
CLNN
Clene
3.17
Buy$40.00919.11% Upside
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.50
Moderate Buy$12.00375.06% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2.50
Moderate Buy$30.00364.40% Upside

Current Analyst Ratings Breakdown

Latest AIM, DARE, CLNN, and TPST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
6/30/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
5/8/2025
Clene Inc. stock logo
CLNN
Clene
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$84.00 ➝ $33.00
5/8/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/23/2025
Clene Inc. stock logo
CLNN
Clene
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$146K47.12N/AN/A$0.20 per share45.03
Clene Inc. stock logo
CLNN
Clene
$340K95.47N/AN/A($1.06) per share-3.70
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$10K2,235.51N/AN/A($0.69) per share-3.66
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$5.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
Clene Inc. stock logo
CLNN
Clene
-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/14/2025 (Estimated)

Latest AIM, DARE, CLNN, and TPST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.23N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.55N/AN/AN/A$0.14 millionN/A
8/6/2025Q2 2025
Clene Inc. stock logo
CLNN
Clene
-$0.49N/AN/AN/A$0.06 millionN/A
5/13/2025Q1 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/13/2025Q1 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.71-$3.16+$0.55-$3.16N/AN/A
5/7/2025Q1 2025
Clene Inc. stock logo
CLNN
Clene
-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
Clene Inc. stock logo
CLNN
Clene
N/A
1.36
1.36
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.56
0.56
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
1.70
1.70

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Clene Inc. stock logo
CLNN
Clene
23.28%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
Clene Inc. stock logo
CLNN
Clene
35.30%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.00%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
20764,00068.74 millionNot Optionable
Clene Inc. stock logo
CLNN
Clene
1008.27 million5.35 millionOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
308.85 million8.50 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
203.68 million3.51 millionOptionable

Recent News About These Companies

TPST Tempest Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$9.01 +0.36 (+4.10%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Clene stock logo

Clene NASDAQ:CLNN

$3.92 +0.11 (+2.75%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.53 +0.03 (+1.04%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$6.46 +0.16 (+2.54%)
As of 09:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.